Pharmacological Activation of HMN for OSA Aim 2

Recruiting in Palo Alto (17 mi)

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1 & 2

Recruiting

Sponsor: Brigham and Women's Hospital

Trial Summary

What is the purpose of this trial?

This trial is testing different medications given before sleep to help patients with obstructive sleep apnea. These patients have weak throat muscles when they fall asleep, causing their airways to collapse. The medications aim to keep these muscles active during sleep to prevent this collapse. Initial findings in a study of 73 adults with moderate or severe OSA reported that the cannabinoid, dronabinol, reduced the number of airway collapse events per hour from 25.9 to 15.2 (2.5 mg dose) and 13.0 (10 mg dose).

Eligibility Criteria

Inclusion Criteria

AHI > 10 events/h during NREM supine sleep

Participant Groups

Group I: LTM1201AZ Experimental Treatment 1 Intervention

LTM1201AZ capsule before bedtime

Group II: LTM1201AT Experimental Treatment 1 Intervention

LTM1201AT capsule before bedtime

Group III: LTM1201AG Experimental Treatment 1 Intervention

LTM1201AG capsule before bedtime

Group IV: LTM1201AD Experimental Treatment 1 Intervention

LTM1201AD capsule before bedtime

Group V: Placebo Placebo Group 1 Intervention

Placebo capsule before bedtime

Find a Clinic Near You

Research Locations Nearby Select from list below to view details:

Brigham and Women's Hospital Boston, MA

Who Is Running the Clinical Trial?

Brigham and Women's Hospital Lead Sponsor

References